Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Piper Sandler Maintains Overweight on Aptose Biosciences, Lowers Price Target to $5-Report Released on 31 January 2024

Author: Benzinga Newsdesk | February 01, 2024 04:09pm

Piper Sandler analyst Edward Tenthoff maintains Aptose Biosciences (NASDAQ:APTO) with a Overweight and lowers the price target from $12 to $5.

Posted In: APTO